It’s officially spring – the season of growth and renewal 🌸 It’s the perfect time for self-reflection and intention setting. As you take on some spring cleaning, remember to take some time to declutter your mind too 😌
Here’s what’s in store for you in today’s issue:
Why the UK is becoming a psychedelic hotspot
Growing peyote sustainably
Natural vs. synthetic psilocybin
Ketamine + Parkinson’s meds
And more.
In this episode of the Daily Mushroom podcast, we have Dr. Pam Kryskow, a psychedelic researcher, medical doctor, and the medical lead for ketamine-assisted therapy for the Roots to Thrive program. Pam shares the benefits of psychedelic therapy in group settings and how her hiking “trips” helped her cope with daily trauma experienced in her previous job as a firefighter.
The UK is on a mission to create a world-leading clinical research ecosystem that’s more efficient and effective than ever before – and many psychedelic companies are taking advantage of the regulatory changes.
To reach this goal, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) now allows “real world data” (data collected from patients and healthcare systems outside of clinical trials) to aid in the drug approval process
This may bring psychedelic therapies to market much faster not only in the UK, but also in Australia, Canada, Singapore and Switzerland, as the MHRA joined a coalition with these countries called the Access Consortium.
Additionally, the UK may reschedule psilocybin to Schedule 2, reducing barriers to clinical research.
Just yesterday, COMPASS Pathways (CMPS) announced a strategic partnership to launch a major psychedelic research center in the UK.
Other companies to keep an eye on that may benefit from these changes include Albert Labs (ABRT), Awakn Life Sciences (AWKN), Small Pharma (DMT), Beckley Psytech, Eleusis.
sustainable
|
|
Is psilocybin the only beneficial compound in magic mushrooms?If synthetic psilocybin is cheaper to produce, why are many psychedelic companies sticking with the natural route? Some believe that consumers would rather take a naturally grown mushroom than something formulated in a lab. Other researchers, like those at Filament Health (FH), think the other unknown compounds in the mushroom could provide additional benefits that complement psilocybin. This theory, called “the entourage effect”, is popular in the cannabis industry too. Filament Health is committed to all-natural psilocybin and has developed a way to produce it at a low cost. They just received a second patent for the extraction and standardization of natural psilocybin. |
Ketamine + Parkinson’s medsThe most common Parkinson’s medication, Levodopa, causes involuntary muscle movements in most patients who take it long-term. PharmaTher (PHRM) found that a low dose of ketamine reduces these muscle spams in 100% of Parkinson’s patients — but it’s unclear by how much or for how long 🤔 However, a separate study from 2016 found that low doses of ketamine reduced this side effect for up to one month and also eased depression. PharmaTher is confident that the results will pave the way for a Phase 3 trial. |
Mind Cure Health (MCUR) and Core One Labs (COOL) appear to be running out of money as they look for strategic takeover opportunities 😬
Biomind Labs (BMND) is launching a commercial clinical trial on its proprietary mescaline-based formulation. The drug targets inflammation, which the company believes is the root cause of many forms of depression.
Novamind (NM) is piloting a group therapy model for psychedelic sessions and integration sessions in groups of 4-10 people. Both drop-in sessions and multi-week programs will be offered.
Tryp Therapeutics (TRYP) began enrolling patients for a Phase 2 trial on psilocybin for binge eating. The company is using non-proprietary synthetic psilocybin to generate data quickly while developing a proprietary formulation
Hazel Park became the third city in Michigan to decriminalize a range of psychedelics, following Ann Arbor and Detroit.
Activists continue to push for statewide ballot initiative to legalize the possession, cultivation, and sharing of natural psychedelics and set up a system for therapeutic use.
A bill that would create psychedelic treatment centers for psilocybin and MDMA therapy was approved by a legislative committee, advancing to floor consideration.
Treatments would be focused on veterans, first responders, healthcare workers, and those from underserved communities with life-threatening mental illness.
|
|
